Education
About Us
Working with TipRanks
Follow Us
60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ:SXTP
RESEARCH TOOLSreports
Top Page
60 Degrees Pharmaceuticals, Inc.
(NASDAQ:SXTP)
Rating:39Underperform
Price Target:
$2.50
â–²(15.74%Upside)
Positive Factors
Market Potential
The company survey indicates that Babesiosis prevalence could be significantly higher than CDC estimates, suggesting a larger potential market for Tafenoquine.
Regulatory Advantage
Arakoda was granted FDA Orphan Drug Designation for the treatment of babesiosis, which is a rare seasonal disease.
Sales Growth
Arakoda sales continue to grow, with net product revenues reaching $607,574 in FY24, a significant increase from $253,573 in FY23.
Negative Factors
Earnings Performance
Q1 earnings per share were below estimates due to higher than forecast SG&A expenses.
Evaluation Challenge
It is difficult to evaluate the company prior to data from the clinical babesiosis program.
Market Insight
There is little insight into the malaria market and the company's findings from its pilot program are awaited.
60 Degrees Pharmaceuticals, Inc. (SXTP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.18M
Dividend YieldN/A
Average Volume (3M)207.65K
Price to Earnings (P/E)―
Beta (1Y)2.35
Revenue Growth109.29%
EPS Growth-206.99%
CountryUS
Employees3
SectorHealthcare
Sector Strength53
IndustryBiotechnology
Share Statistics
EPS (TTM)-27.07
Shares Outstanding1,472,891
10 Day Avg. Volume540,866
30 Day Avg. Volume207,649
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)-13.77
Price to Sales (P/S)0.00
P/FCF Ratio-303.43
Enterprise Value/Market Cap109.03
Enterprise Value/Revenue164.48
Enterprise Value/Gross Profit1.32K
Enterprise Value/Ebitda-12.62
Forecast
1Y Price Target
$7.00Price Target Upside224.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model
Company Description60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
How the Company Makes Money60 Degrees Pharmaceuticals, Inc. generates revenue through the sale of its pharmaceutical products, primarily targeting tropical diseases. The company leverages strategic partnerships with global health organizations and governments to distribute its treatments in affected regions. Additionally, it may receive funding and grants to support research and development efforts aimed at expanding its product portfolio and enhancing the efficacy of its treatments. These collaborations and funding opportunities are crucial in driving the company's revenue and growth in the global health sector.
60 Degrees Pharmaceuticals, Inc. Financial Statement Overview
Summary
The company is facing significant financial challenges, with declining revenues, persistent losses, and negative cash flow. While there have been some improvements in equity and debt levels, the overall financial health remains weak, warranting a low score.Income Statement
The company has been experiencing declining revenues, with a significant drop in total revenue from 2020 to 2023. Gross profit margin has been negative in recent years, indicating cost management issues. Net profit margin has been consistently negative, reflecting ongoing unprofitability. Despite some revenue growth in 2024, profitability remains a major concern.35
Negative
Balance Sheet
The debt-to-equity ratio improved significantly from previous years due to reduced total liabilities, but the company still has challenges with negative equity in past years. In 2024, equity became positive, which is a positive sign. The equity ratio indicates a relatively higher reliance on equity compared to previous years.40
Negative
Cash Flow
The company has struggled with negative operating cash flow in recent years, indicating challenges with cash generation from core operations. Free cash flow has also been negative, reflecting ongoing investment and financing needs. Positive financing cash flows suggest reliance on external funding.30
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 655.39K | 607.57K | 253.57K | 223.21K | 1.16M | 2.18M | Gross Profit |
| 262.79K | 222.81K | -220.98K | -209.16K | 309.60K | 1.48M | EBIT |
| -10.29M | -9.71M | -5.15M | -1.75M | -1.12M | -418.13K | EBITDA |
| -10.25M | -7.88M | -1.43M | -2.11M | -1.01M | -341.17K | Net Income Common Stockholders |
| -10.25M | -7.95M | -3.77M | -6.18M | -4.25M | -3.03M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 3.45M | 3.39M | 2.14M | 264.87K | 115.40K | 191.70K | Total Assets |
| 5.98M | 5.76M | 7.78M | 1.30M | 1.39M | 2.61M | Total Debt |
| 0.00 | 155.89K | 172.67K | 22.42M | 18.80M | 15.92M | Net Debt |
| -3.45M | -1.50M | -1.97M | 22.15M | 18.69M | 15.73M | Total Liabilities |
| 146.50K | 1.87M | 2.99M | 25.45M | 19.55M | 20.68M | Stockholders Equity |
| 4.03M | 4.04M | 4.87M | -23.58M | -17.58M | -17.50M |
| Cash Flow | Free Cash Flow | ||||
| -4.68M | -5.83M | -4.66M | -1.07M | -684.50K | -238.28K | Operating Cash Flow |
| -4.51M | -5.65M | -4.54M | -1.01M | -649.11K | -167.30K | Investing Cash Flow |
| -176.78K | -1.89M | -115.89K | -60.13K | -35.39K | -70.98K | Financing Cash Flow |
| 6.85M | 7.05M | 6.47M | 1.22M | 611.23K | 277.36K |
60 Degrees Pharmaceuticals, Inc. Technical Analysis
Negative
2.16
Price Trends
2.59
Negative
2.49
Negative
4.12
Negative
Market Momentum
-0.06
Positive
37.85
Neutral
4.41
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXTP, the sentiment is Negative. The current price of 2.16 is below the 20-day moving average (MA) of 2.51, below the 50-day MA of 2.59, and below the 200-day MA of 4.12, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 37.85 is Neutral, neither overbought nor oversold. The STOCH value of 4.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SXTP.
60 Degrees Pharmaceuticals, Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.34B | 3.36 | -45.10% | 3.39% | 16.81% | -0.03% | |
39 Underperform | $3.18M | ― | -181.43% | ― | 109.29% | -206.99% | |
| $5.47M | ― | -221.23% | ― | ― | ― | ||
32 Underperform | $3.39M | ― | -217.01% | ― | ― | 45.99% | |
| $4.18M | ― | -99.38% | ― | ― | ― | ||
| $2.47M | ― | -1092.96% | ― | ― | ― | ||
15 Underperform | $4.46M | ― | -206.26% | ― | ― | 75.68% |
* Healthcare Sector Average
Performance Comparison
SXTP
60 Degrees Pharmaceuticals, Inc.
2.07
-13.98
-87.10%
ATNF
180 Life Sciences
0.93
-0.71
-43.29%
ADIL
Adial Pharmaceuticals
0.24
-1.03
-81.10%
SILO
Silo Pharma
0.60
-0.36
-37.50%
ALZN
Alzamend Neuro
2.97
-32.94
-91.73%
DRMA
Dermata Therapeutics
0.71
-1.77
-71.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.